Background Patients with chronic kidney disease (CKD) have an increased risk of venous
thromboembolism (VTE) and atrial fibrillation (AF). Anticoagulants have not been studied in …

Atrial fibrillation (AF) and chronic kidney disease (CKD) are strictly related; several
independent risk factors of AF are often frequent in CKD patients. AF prevalence is very …

The consensus of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in
atrial fibrillation (AF) has been published in 2017 which provided useful clinical guidance for …

Background: Non–vitamin K oral anticoagulants have become the standard therapy for
preventing stroke and ischemic thromboembolism in most patients with atrial fibrillation (AF) …

Objective: A lack of clarity persists regarding the efficacy and risks associated with direct oral
anticoagulants (DOACs) in end-stage renal disease (ESRD) patients with atrial fibrillation …

The frequent coexistence in daily clinical practice of chronic kidney disease (CKD) and atrial
fibrillation (AF), especially in the elderly, represents a conundrum for physicians, mainly …

Background Concomitant atrial fibrillation and end‐stage renal disease is common and
associated with an unfavorable prognosis. Although oral anticoagulants have been well …

Purpose Patients with atrial fibrillation (AF) and end-stage renal disease on chronic
hemodialysis are at risk for thromboembolic and bleeding events. We aimed to perform a …

Objective: To evaluate the role of oral anticoagulation in patients with stage 5 chronic kidney
disease (CKD-5) or end-stage kidney disease (ESKD). Data Sources: A literature search of …

Background & Objectives Comparison of clinical outcomes across anticoagulation regimens
using different apixaban dosing or warfarin is not well-defined in patients with nonvalvular …